China Issues New Risk Classification Rule For GMP Inspections
This article was originally published in PharmAsia News
The new risk-based regulation highlights recordkeeping and high-risk products with stricter enforcement for repeat offenders. Meanwhile, SFDA is also implementing an electronic monitoring system to improve drug safety.
You may also be interested in...
SHANGHAI - China's State FDA released its long-awaited good manufacturing practices guidelines for pharmaceutical products Feb. 12, which will begin to be implemented in all new drug manufacturing sites in March
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.
China insists there is no double standard and won’t tolerate any quality issues in its centralized procurement process.